Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019; 18: 103-107
Феномен конверсии группы крови донора на группу крови реципиента после AB0-несовместимой трансплантации гемопоэтических стволовых клеток у пациента с синдромом Вискотта–Олдрича
https://doi.org/10.24287/1726-1708-2019-18-2-103-107Аннотация
В статье представлено клиническое наблюдение пациента с синдромом Вискотта–Олдрича, у которого через 6 месяцев после проведения трансплантации гемопоэтических стволовых клеток (ТГСК) от разногруппного по ABO-системе донора была верифицирована собственная группа крови, что изначально расценили как первый признак миелоидного отторжения. В процессе диагностики подтвердилась гипотеза абсорбции на эритроцитах донора белков системы АВ0, принадлежащих реципиенту, а изучение группового иммунологического профиля позволило исключить риски гемолитических реакций и прогнозировать благоприятный исход у пациента. Родители дали согласие на использование информации о ребенке в статье.
Список литературы
1. Ochs H.D. The Wiskott–Aldrich syndrome. Springer Semin. Immunopathol 1998; 19: 435–58.
2. Ochs H.D., Filipovich A.H., Veys P., Cowan M.J., Kapoor N. Wiskott– Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009; 15 (1): 84–90.
3. Derry J.M., Ochs H.D., Francke U. Isolation of a novel gene mutated in Wiskott–Aldrich syndrome. Cell 1994; 78: 635–44.
4. Jin Y., Mazza C., Christie J.R., Giliani S., Fiorini M., Mella P., et al. Mutations of the Wiskott–Aldrich Syndrome Protein (WASP): hot-spots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104 (13): 4010–9.
5. Ochs H.D., Thrasher A.J., The Wiskott– Aldrich syndrome. J Allergy Clin Immunol 2006; 117: 725–38.
6. Devriendt K., Kim A.S., Mathijs G., Frints S.G., Schwartz M., Van Den Oord J.J., et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001; 27: 313–7.
7. Moratto D., Giliani S., Bonfim C., Mazzolari E., Fischer A., Ochs H.D., et al. Longterm outcome and lineage-spe-cific chimerism in 194 patients with Wiskott–Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood 2011; 118: 1675.
8. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., Schulz A., Thrasher A.J., Mazzolari E., et al. Long-term outcome following hematopoietic stemcell transplantation in Wiskott–Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008; 111 (1): 439–45.
9. Andreani M., Testi M., Battarra M., Lucarelli G. Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism 2011 Jan; 2 (1): 21–2.
10. Yamakami K. The individuality of semen, with reference to its property of inhibiting specifically isoagglutination. J Immunol 1926; 12: 185–9.
11. Koda Y., Tachida H., Pang H., Liu Y., Soejima M., Ghaderi A.A., et al. Contrasting patterns of polymorphisms at the ABO-secretor gene (FUT2) and plasma alpha(1,3) fucosyltransferase gene (FUT6) in human populations. Genetics 2001; 158: 747–56.
12. Kudo T., Iwasaki H., Nishihara S., Shinya N., Ando T., Narimatsu I., et al., Molecular genetic analysis of the human Lewis histo-blood group system. II. Secretor gene inactivation by a novel single missense mutation A385T in Japanese nonsecretor individuals. J Biol Chem 1996; 271, 9830–7.
13. Hult A.K., Dykes J.H., Storry J.R., Olsson M.L. A and B antigens acquired by group O donor-derived erythrocytes following ABO-nonidentical transfusion or minor ABOincompatible haematopoietic stem cell transplantation. Trans Med 2017; 27: 181–91.
14. Holbro A., Stern M., Infant L., O’Meara A., Drexler B., Frey B.M., et al. Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation. Transfusion 2015; 55: 64–9.
15. Stussi G., Seebach L., Muntwyler J., Schanz U., Gmur J., Seebach J.D. Graftversus- host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience. Br J Haematol 2001; 113: 251–3.
16. Балашов Д.Н., Трахтман П.Е. Особен- ности проведения трансфузионной те- рапии у пациентов после транспланта- ции гемопоэтических стволовых клеток. Обзор литературы. Онкогематология 2013; 8 (3): 42–7.
17. Yeates L., Slatter M.A., Gennery A.R. Infusion of Sibling Marrow in a Patient with Purine Nucleoside Phosphorylase Deficiency Leads to Split Mixed Donor Chimerism and Normal Immunity. Front Pediatr 2017; 5: 143.
18. Abbas A.K., Lichtman A.H., Pillai S. Cellular and Molecular Immunology (eighth edition). Philadelphia, PA, USA; Elsevier Saunders, 2015.
Pediatric Hematology/Oncology and Immunopathology. 2019; 18: 103-107
The phenomenon of conversion of the donor-derived blood group to the patient’s original blood group after ABO-incompatible hematopoietic stem cell transplantation in a patient with Wiskott–Aldrich syndrome
https://doi.org/10.24287/1726-1708-2019-18-2-103-107Abstract
We present a clinical case of hematopoietic stem cell transplantation (HSCT) in a patient with Wiskott-Aldrich syndrome. In spite of donor different ABO-system, the own blood group was verified in 6 months after HSCT, which was initially regarded as a risk of myeloid rejection. During the diagnosis, the hypothesis of absorption of the recipient’s ABO-system proteins onto the donorderived red blood cells was confirmed. The study of the immunological profile allowed to exclude the risks of hemolytic reactions and to predict a favorable outcome in the patient. Parents gave their consent to use information about the child in the article.
References
1. Ochs H.D. The Wiskott–Aldrich syndrome. Springer Semin. Immunopathol 1998; 19: 435–58.
2. Ochs H.D., Filipovich A.H., Veys P., Cowan M.J., Kapoor N. Wiskott– Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biol Blood Marrow Transplant 2009; 15 (1): 84–90.
3. Derry J.M., Ochs H.D., Francke U. Isolation of a novel gene mutated in Wiskott–Aldrich syndrome. Cell 1994; 78: 635–44.
4. Jin Y., Mazza C., Christie J.R., Giliani S., Fiorini M., Mella P., et al. Mutations of the Wiskott–Aldrich Syndrome Protein (WASP): hot-spots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104 (13): 4010–9.
5. Ochs H.D., Thrasher A.J., The Wiskott– Aldrich syndrome. J Allergy Clin Immunol 2006; 117: 725–38.
6. Devriendt K., Kim A.S., Mathijs G., Frints S.G., Schwartz M., Van Den Oord J.J., et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001; 27: 313–7.
7. Moratto D., Giliani S., Bonfim C., Mazzolari E., Fischer A., Ochs H.D., et al. Longterm outcome and lineage-spe-cific chimerism in 194 patients with Wiskott–Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood 2011; 118: 1675.
8. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., Schulz A., Thrasher A.J., Mazzolari E., et al. Long-term outcome following hematopoietic stemcell transplantation in Wiskott–Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008; 111 (1): 439–45.
9. Andreani M., Testi M., Battarra M., Lucarelli G. Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism 2011 Jan; 2 (1): 21–2.
10. Yamakami K. The individuality of semen, with reference to its property of inhibiting specifically isoagglutination. J Immunol 1926; 12: 185–9.
11. Koda Y., Tachida H., Pang H., Liu Y., Soejima M., Ghaderi A.A., et al. Contrasting patterns of polymorphisms at the ABO-secretor gene (FUT2) and plasma alpha(1,3) fucosyltransferase gene (FUT6) in human populations. Genetics 2001; 158: 747–56.
12. Kudo T., Iwasaki H., Nishihara S., Shinya N., Ando T., Narimatsu I., et al., Molecular genetic analysis of the human Lewis histo-blood group system. II. Secretor gene inactivation by a novel single missense mutation A385T in Japanese nonsecretor individuals. J Biol Chem 1996; 271, 9830–7.
13. Hult A.K., Dykes J.H., Storry J.R., Olsson M.L. A and B antigens acquired by group O donor-derived erythrocytes following ABO-nonidentical transfusion or minor ABOincompatible haematopoietic stem cell transplantation. Trans Med 2017; 27: 181–91.
14. Holbro A., Stern M., Infant L., O’Meara A., Drexler B., Frey B.M., et al. Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation. Transfusion 2015; 55: 64–9.
15. Stussi G., Seebach L., Muntwyler J., Schanz U., Gmur J., Seebach J.D. Graftversus- host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: a single-centre experience. Br J Haematol 2001; 113: 251–3.
16. Balashov D.N., Trakhtman P.E. Osoben- nosti provedeniya transfuzionnoi te- rapii u patsientov posle transplanta- tsii gemopoeticheskikh stvolovykh kletok. Obzor literatury. Onkogematologiya 2013; 8 (3): 42–7.
17. Yeates L., Slatter M.A., Gennery A.R. Infusion of Sibling Marrow in a Patient with Purine Nucleoside Phosphorylase Deficiency Leads to Split Mixed Donor Chimerism and Normal Immunity. Front Pediatr 2017; 5: 143.
18. Abbas A.K., Lichtman A.H., Pillai S. Cellular and Molecular Immunology (eighth edition). Philadelphia, PA, USA; Elsevier Saunders, 2015.
